AR
ARMP.US Armata Pharmaceuticals Inc
- Market cap
- USD 144M
- P/E
- -
- P/B
- 2.11x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ARMP.US undervalued?
Graham numberThe Graham number of Armata Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Armata Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Armata Pharmaceuticals Inc yet.
Armata Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa. The company is based in Los Angeles, California. Armata Ph…
Full company profileArmata Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Armata Pharmaceuticals Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 260K | 115K | 0.00 | 31.0K | 823K | 4.47M | 5.51M | 4.53M | 5.17M | 4.90M | 8.63M |
| Gross Profit | -109K | -259K | -1.35M | -1.35M | -13.6M | -15.5M | -29.5M | 3.56M | -29.3M | 3.37M | -6.84M |
| Operating Income | -23.4M | -16.2M | -12.5M | -19.1M | -21.6M | -23.8M | -36.9M | -40.9M | -42.4M | -31.2M | -35.3M |
| EBITDA | -13.5M | -9.98M | -9.54M | -17.2M | -20.4M | -21.9M | -36.0M | -65.4M | -6.85M | -156M | 46.7M |
| Net Income | -18.8M | -12.8M | -12.1M | -19.5M | -22.2M | -23.2M | -36.9M | -69.0M | -18.9M | -174M | 18.2M |
| EPS | -2,681 | -28 | -36 | -2.49 | -1.35 | -0.96 | -1.08 | -1.91 | -0.52 | -4.80 | 0.29 |
| Balance Sheet | |||||||||||
| Total Assets | 18.2M | 11.1M | 11.9M | 25.5M | 39.5M | 69.8M | 108M | 98.4M | 86.4M | 76.9M | 84.5M |
| Total Liabilities | 8.47M | 3.41M | 3.41M | 10.9M | 20.7M | 44.4M | 71.8M | 130M | 134M | 295M | 259M |
| Shareholders' Equity | 9.72M | 7.73M | 8.47M | 14.6M | 18.9M | 25.4M | 36.1M | -32.1M | -48.0M | -219M | - |
| Cash & Short-term Investments | 5.71M | 5.13M | 8.16M | 6.03M | 9.65M | 10.3M | 14.9M | 13.5M | 9.29M | 8.69M | 18.3M |
| Total Debt | 803K | - | - | 2.86M | 13.2M | 38.0M | 48.8M | 120M | 127M | 288M | 252M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -10.6M | -9.19M | -9.38M | -15.6M | -18.3M | -23.6M | -32.5M | -47.4M | -37.6M | -25.8M | -26.6M |
| Capital Expenditure | 279K | 58.0K | 44.0K | 131K | 824K | 1.30M | 2.21M | 8.14M | 1.88M | 542K | 228K |
| Free Cash Flow | -10.9M | -9.25M | -9.43M | -15.7M | -19.1M | -24.9M | -34.7M | -55.6M | -39.4M | -26.3M | -26.8M |
| Ratios | |||||||||||
| ROE | -193.7% | -166.1% | -142.9% | -133.5% | -117.6% | -91.2% | -102.3% | - | - | - | - |
| ROA | -103.5% | -115.3% | -101.9% | -76.5% | -56.1% | -33.2% | -34.2% | -70.2% | -21.9% | -226.1% | 21.5% |
| Net Profit Margin | -7,245.4% | -11,163.5% | - | -62,835.5% | -2,695.1% | -517.5% | -670.2% | -1,524.5% | -365.6% | -3,544.0% | 211.0% |
| Debt to Equity | 0.08x | - | - | 0.20x | 0.70x | 1.50x | 1.35x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Armata Pharmaceuticals Inc dividends
Armata Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:14 on May 10, 2019.
Who owns Armata Pharmaceuticals Inc
- Insiders 67.64%
- Institutions 13.93%
- Public & others 18.44%
- Shares outstanding 37.2M
- Free float 11.9M
Armata Pharmaceuticals Inc company profile
- Company name
- Armata Pharmaceuticals Inc
- Ticker
- ARMP.US
- Exchange
- USA Stocks
- Listed since
- Mar 9, 2011
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 61
- Fiscal year end
- December
- Address
- 5005 McConnell Avenue, Los Angeles, CA, United States, 90066
- Phone
- 310 665 2928
- Website
- armatapharma.com
About Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
Armata Pharmaceuticals Inc management
5- Dr. Deborah L. Birx M.D.CEO & Director · born 1957
- Mr. David D. HouseChief Financial Officer · born 1984
- Dr. Pierre Kyme Ph.D.Chief Business Officer · born 1978
- Mr. Peter HubbardVice President of Operations
- Ms. Bani Tchekanova Ph.D.Head of Regulatory Strategy & Operations